



JOHNS HOPKINS  
BLOOMBERG SCHOOL  
of PUBLIC HEALTH

Department of Population,  
Family & Reproductive Health  
BESAFE

# SPEAKER BIOS

September 23 - 24, 2026

**THE 2026 BESAFE CONFERENCE**  
*Protecting Patients from Substandard and  
Falsified Medical Products*

**HOPKINS BLOOMBERG CENTER  
555 PENNSYLVANIA AVENUE NW  
WASHINGTON, DC 20001**





**Saifuddin Ahmed, PhD, MBBS, Professor, Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health**

Dr. Saifuddin Ahmed is a distinguished physician, demographer, and epidemiologist, and serves as the Principal Investigator of the BESAFE Initiative – Behavioral and Educational Strategies for Avoiding Falsified Medicine Exposure. A professor at the Johns Hopkins Bloomberg School of Public Health, Dr. Ahmed has dedicated his career to advancing global health through rigorous research, policy engagement, and evidence-based program design. He has served as a technical advisor to the World Health Organization and numerous international agencies, contributing to the development of frameworks aimed at strengthening health systems and ensuring the quality and safety of medicines. His pioneering research has significantly influenced maternal health, family planning, and health systems strengthening, and more recently, the global response to substandard and falsified medical products. Dr. Ahmed's scholarly impact is exceptional—he has authored over 200 peer-reviewed publications in leading scientific journals such as *The Lancet*, *The Lancet Global Health*, and *BMJ Global Health*, collectively garnering more than 16,000 citations. His mentorship, scientific rigor, and commitment to translating research into policy and practice continue to inspire a new generation of global health leaders working toward safer, more equitable access to medicines worldwide.



**Matthew Millhollin, Acting Deputy Executive Associate Director, Homeland Security Investigations**

Matthew is a distinguished senior executive focused in global investigations and security with decades of domestic and international experience protecting U.S. supply chains, intellectual property, and financial institutions. Throughout Matthew's leadership career, he has led large-scale international coalitions to advance national security and counter transnational threats. Matthew is a proven strategic leader with a track record of mitigating vulnerabilities in finance, public safety, and information technology systems.

Matthew has decades of experience residing and leading teams in Europe, Middle East, South Asia, and Latin America. He is skilled in building relationships with businesses, government officials, and agencies towards mutually beneficial outcomes. Matthew has an established reputation for turning around team cultures and operations, with a focus on performance standards, collaboration, and diversity and inclusion.

As a senior executive, Matthew has an extensive history of building diverse, inclusive, high-performing teams that align resources, operations, and technologies to fortify systems against global and domestic threats. Top Secret/SCI Security Clearance.



**Jean Christophe Rusatira, MD, PhD, MPH, Sr. Program Officer, BESAFE, Johns Hopkins Bloomberg School of Public Health**

Dr. Jean Christophe Rusatira is a physician, epidemiologist, and population health researcher with over 15 years of experience in public health research, policy, and program implementation. He holds a Medical Degree from the National University of Rwanda and both an MPH and a PhD from the Johns Hopkins Bloomberg School of Public Health. His work focuses on population health, safe medicines, road safety, and regulatory affairs, emphasizing evidence-based policy and program innovation in the U.S. and Sub-Saharan Africa. He led the development of the Demographic Dividend Effort Index (DDEI) across six African countries and the BESAFE initiative on falsified medicines at Johns Hopkins. Dr. Rusatira has consulted for the World Health Organization, Gates Foundation and the World Bank. He founded Healthy People Rwanda, co-founded the International Youth Alliance for Family Planning (IYAFP), and founded Matriarch Coffee, a social-impact company connecting his family's Rwandan coffee farms to the U.S. market.



**Patrick Caubel, MD, Chief Safety Officer, Pfizer**

Dr. Patrick Caubel has more than 25 years of experience in the life science industry, leading pharmacovigilance and epidemiology teams at Pfizer, Sanofi-Genzyme, Sanofi-Pasteur, and Johnson & Johnson. A trained ob-gyn physician who practiced for nearly 20 years before moving full-time into drug development and pharmaceutical research, Dr. Caubel also holds a PhD in Pharmacology and an MBA from Rutgers University. Dr. Caubel's recent research interests are about increasing utilization of Real World Evidence data and controlled development of Artificial Intelligence tools for Drug Safety monitoring. Dr. Caubel has 86 peer-reviewed publications referenced in Embase and is regularly cited for his work in public health, drug safety and pharmaco-epidemiology. With a special interest in ensuring global safe supply of trusted medications, he is the co-founder of the BESAFE program together with Prof. Saifuddin Ahmed (JHU) and Mr. Lev Kubiak (Pfizer). Today he leads a global team as Pfizer's Chief Safety Officer.



**Libby Baney, JD, Senior Advisor, Alliance for Safe Online Pharmacies (ASOP)**

Libby embraces "Love What You Do." A partner at Faegre Drinker LLP, Libby works on drug safety, pharmacy, supply chain, online pharmacy, and direct-to-consumer healthcare issues. Libby represents the Alliance for Safe Online Pharmacies (ASOP Global), the ASOP Global Foundation, and other nonprofit and corporate entities. She has built trusted relationships with U.S. and international agencies. Clients hire Libby for her strategic insight, collaborative approach, and tenacious, results-oriented work product. In addition to advising clients, Libby serves as part of Faegre Drinker's Board. Outside of work, Libby enjoys early morning workouts, scuba, cycling through Washington, D.C., and spending quality time with her family.



## **Jonas Congelli, RPh, Associate Executive Director, NCODA**

Jonas graduated from Albany College of Pharmacy in 1989 and brings decades of experience in oncology pharmacy, encompassing inpatient hospital settings, outpatient care, and community oncology practice. He currently serves as the Associate Executive Director of NCODA, a not-for-profit organization dedicated to enhancing oncology sites of care with medically integrated services.

Previously, he was the Chief Strategy Officer for Hematology Oncology Associates of Central New York (HOACNY), a large multispecialty community oncology practice with three locations, 20 physicians and over 300 employees. In addition, he has held leadership and advisory roles in several prominent organizations, including Athena Oncology, NCODA, Community Oncology Pharmacy Association (COPA), Empire State Hematology Oncology Society (ESHOS), International Oncology Network, ONCare Alliance and Flatiron Health.

With a deep commitment to advancing patient-centered oncology care, Jonas continues to drive innovation in medically integrated pharmacy services. His leadership and strategic vision have helped shape the future of oncology practice, fostering collaboration and improving outcomes for patients nationwide.



## **Angel Melendez, VP, Global Security Operations, Pfizer**

Angel M. Melendez is Vice President, Global Security Operations at Pfizer, where he oversees global efforts to protect colleagues, patients, products, and business operations through security risk management, crisis response, product integrity, and pharmaceutical crime prevention. With more than 40 years of experience spanning corporate security, law enforcement, and military service, he previously served with U.S. Homeland Security Investigations (HSI), including as Special Agent in Charge for New York and Puerto Rico. He has led initiatives focused on transnational crime, threat mitigation, executive protection, crisis management, intellectual property protection, and public safety. A retired member of the U.S. Senior Executive Service and Gulf War veteran, Mr. Melendez currently serves on several public safety and security-related boards and industry initiatives dedicated to protecting patients and communities.



## **Anthony Zook, PhD, Associate Vice President, Global Security, Merck & Co., Inc.**

Tony serves as Merck's Associate Vice President of Global Security and head of Merck's global Product Integrity program. This includes responsibility for the development and execution of the Company's strategy that protects Merck products from illicit actions, including counterfeiting, diversion, tampering, and theft. His work focuses on securing the supply chain, investigation and enforcement of illicit activity, and building stakeholder awareness to this growing threat to public safety. He is particularly interested in investigations and forensic analysis of counterfeit medicines, applications of advanced intelligence analytics to support these investigations, and collaborative relationships with regulatory and enforcement agencies who can best mitigate risks to patients.

**Abha Kundi, JD, MPH, Counsel, ArentFox Schiff**

Abha Kundi is counsel at ArentFox Schiff, where she advises pharmaceutical industry clients on drug safety and supply chain security matters, including incident response, recalls, shortages, import and export compliance, distribution practices, licensure, and manufacturing oversight, among other issues. She brings nearly 15 years of experience at the U.S. Food and Drug Administration, where she most recently served as Team Lead of the Office of Drug Security, Integrity & Response within the Office of Compliance's Division of Supply Chain Integrity and Supply Chain Security Branch at the Center for Drug Evaluation and Research, overseeing drug supply chain incident response, recalls, and enforcement actions that contained public health exposure to potentially harmful drugs and earned her Agency- and Center-level recognition. For over a decade, she also developed and directed FDA's Drug Supply Chain Security Act (DSCSA) program, playing a key role in promulgating its implementing regulations and guidance for manufacturers, repackagers, wholesale distributors, third-party logistics providers, and dispensers on securing the pharmaceutical supply chain.

**Eddie Agrait, Americas Regional Director, PSI**

Mr. Eddie Agrait is the Director of the Americas at the Institute for Pharmaceutical Safety (PSI), where he is responsible for improving and strengthening relationships between governments and the pharmaceutical industry while conducting capacity building and training for law enforcement agencies in the Americas. PSI is a not-for-profit pharmaceutical industry association whose main objectives are to protect public health and safety by exchanging information on counterfeiting, illegal diversion and theft of pharmaceutical products, supporting PSI Members, law enforcement agencies and regulatory authorities, establish liaison with national and international organisations in the field of counterfeit and illicit medicines, gather information and intelligence on all aspects of illegal medicines and provide training and sensitisation to law enforcement in relation to pharmaceutical crimes.

Prior to joining PSI, Mr. Agrait served as Chief of Staff for the Director of International Operations, Homeland Security Investigations (HSI). As Chief of Staff, Mr. Agrait served as the Senior Advisor to the Director of International Operations. Mr. Agrait has served in multiple roles within HSI, including as Attaché for the Southern Cone of the Americas, Buenos Aires, Argentina. Prior to this, he served as Operations Chief for Mexico, a Level 1 Attaché office, the Department of Homeland Security's largest overseas presence. In this role, he was responsible for oversight of the office of the Attaché in Mexico and supervised the program managers at International Operations headquarters.



**Caroline Moreau, MD, PhD, MPH, Professor, Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health**

Caroline Moreau is Professor at the Johns Hopkins Bloomberg School of Public Health, Senior Researcher at the French National Institute of Health and Medical Research (INSERM), and Research Director at the William H. Gates Sr. Institute for Population and Reproductive Health. Her work examines how gender, social class, race, and other forms of social inequality shape sexual and reproductive health across the life course.

Dr. Moreau brings a global perspective to sexual and reproductive health research, with experience spanning high-, middle-, and low-income settings. Since 2010, she has co-led major national sexual and reproductive health research programs in France, including studies on sexuality and sexual health, fertility, and abortion. At Johns Hopkins, she co-leads the Global Early Adolescent Study, the first global longitudinal study to examine how gender socialization influences health and wellbeing across adolescence. As Research Director at the Gates Institute, Dr. Moreau helps shape the Institute's global research agenda and supports efforts to generate new evidence, foster innovation, and strengthen the design, implementation, and evaluation of sexual and reproductive health programs through the Performance Monitoring for Action platform.



**Margot Savoy, MD, MPH, FAFP, Chief Medical Officer, American Academy of Family Physicians**

Margot Savoy is Chief Medical Officer for the American Academy of Family Physicians, Associate Professor of Family & Community Medicine and Urban Bioethics & Population Health at the Lewis Katz School of Medicine.

Dr. Savoy's portfolio includes family physician education, the AAFP accreditation system, journal media, health of the public and science, Centers for Diversity & Health Equity and Women's Health and physician well-being.


Dr. Savoy graduated from the University of Maryland School of Medicine in 2002, completed Family Medicine Residency Program at the Crozer-Keystone Family Medicine Residency Program (Springfield, PA) in 2005 and graduated from the University of North Carolina Chapel Hill Gillings School of Global Public Health in 2008 with a Masters degree in Public Health Leadership with a focus on Public Health Practice. She is certified by the American Board of Family Medicine, the Certifying Commission in Medical Management, the American Board of Medical Quality and is a Fellow of the American Academy of Family Physicians, American Association of Physician Leaders and the Advisory Board Company.



**Chantelle Bailey, PhD, PGCert, Program Manager, Caribbean Regulatory System (CRS), Caribbean Public Health Agency (CARPHA)**

Dr. Bailey recently started her position as Programme Manager at the Caribbean Regulatory System (CRS) within the Caribbean Public Health Agency (CARPHA). She has fifteen years' international technical experience in leading, conducting and publishing several projects which primarily focused on regulation development, monitoring and evaluation to inform strategic policy for health systems. Furthermore, she has substantial expertise in the roles of regulatory frameworks on pharmacovigilance and post-market surveillance initiatives within acute care and primary care settings and clinical audits of health technologies at the drug-medical device interface. Currently, she is investigating intersectoral strategies for addressing the entry of substandard, falsified and unlicensed medical products into legitimate supply chains in the Caribbean.

She holds a PhD in Pharmacy and Pharmaceutical Sciences from the University of Manchester, a CIHR Postdoctoral Research Fellowship in Emergency Medicine undertaken at the University of British Columbia and a CIHR-MITACS Health System Impact Fellowship in Public Policy undertaken at the University of Toronto. Furthermore, she has received specialist training in Regulatory Affairs (PGCert) which focused on the implementation of quality management systems in pharmaceutical and chemical manufacturing.



**Sachiko Ozawa, PhD, MHS, Global Health Economics for Pharmacy, Professor, Division of Practice Advancement and Clinical Education, UNC Eshelman School of Pharmacy**

Sachiko Ozawa is a health economist focused on improving access to medicines and vaccines. Author of over 100 articles, her research on vaccines and substandard and falsified medicines has gained global recognition, including citations by world leaders and coverage by major media outlets. Ozawa works at the intersection between pharmacy and public health to improve the quality, safety, efficacy, and affordability of vaccines in medicines globally. She leads the Global Health Economics for Pharmacy team, focusing on medicine quality, online pharmacies, and vaccine economics. Notable contributions include modeling the impacts of substandard and falsified medicines, characterizing the online accessibility of medications, and estimating the return on investment of vaccinations.

Her work has been presented at the National Press Club, became Health Affairs' top 10 most read articles, cited by the Prime Minister of Canada, tweeted by Bill Gates, and reported by the Washington Post, Forbes, CNN Business, Reuters, National Public Radio (NPR), and other news media.

She currently serves as an expert on the African working group on substandard and falsified medical products led by the African Union Development Agency-NEPAD. She is also a member on the Med Aditus Foundation Board, advancing medication access in Africa.



**Ana Carolina da Silva Macarenco, PharmD, MPH, Risk Management Product Lead, Pfizer**

Dr. Ana Carolina da Silva Macarenco is an accomplished pharmaceutical safety leader and serves as a Senior Manager and Risk Management Product Lead within Pfizer's Worldwide Safety organization. In this role, she oversees the design and implementation of comprehensive global risk-management strategies across therapeutic areas, ensuring that benefit-risk frameworks, post-market surveillance, and risk-minimization measures meet the highest scientific and regulatory standards. Dr. Macarenco has extensive expertise in pharmacovigilance, regulatory science, and product lifecycle management, with a focus on integrating data-driven approaches to enhance patient safety and compliance worldwide. Dr. Macarenco is also an active member of the BESAFE initiative, collaborating with global partners to advance education and awareness on substandard and falsified medical products and strengthen patient safety worldwide. Dr. Macarenco's leadership reflects a deep commitment to advancing a culture of safety, scientific excellence, and collaboration across global markets to strengthen confidence in the quality and integrity of medicines.



**Benyam Muluneh, PharmD, BCOP, FHOPA, Assistant Professor, UNC Eshelman School of Pharmacy**

Benyam Muluneh is an implementation scientist and oncology pharmacist focused on advancing equitable cancer care globally. He leads research on oral anticancer adherence, real-world data, and pharmacy-led interventions across diverse settings, including sub-Saharan Africa.

Muluneh specializes in implementation science and hematology/oncology pharmacotherapy, with a deep commitment to improving equitable access to high-quality cancer care. He leads multi-institutional projects focused on oral chemotherapy adherence, global oncology infrastructure, and pharmacist-driven care models.

A Fellow of the Hematology Oncology Pharmacy Association (FHOPA), Muluneh has received multiple national honors, including the ASHP Best Practices Award and HOPA's Patient Advocacy Award. He supports national and global partnerships aimed at transforming cancer care delivery. He holds both yellow- and purple-belt certifications in Lean Six Sigma and is dedicated to mentoring the next generation of researchers and clinician-leaders.



**Henry Michtalik, MD, MPH, MHS, SFHM, Assistant Professor of Medicine, Johns Hopkins University School of Medicine (BESAFE-BSPH)**

Dr. Henry Michtalik, M.D., M.P.H., M.H.S., S.F.H.M. is an Assistant Professor in the Hospitalist Program at Johns Hopkins University. He is also Core Faculty and an International Consultant for the Armstrong Institute for Patient Safety and Quality of Care and an Affiliate for the Center for Health Services and Outcomes Research at the Bloomberg School of Public Health. He completed the General Internal Medicine Academics Fellowship at Johns Hopkins; has degrees in biostatistics, epidemiology, patient safety and quality of care; has received multiple grants examining hospitalist workload and best-practices for clinical diseases to improve patient outcomes; and completed Lean Sigma and Comprehensive Unit-based Safety Program trainings. Through multi-disciplinary collaboration, he identifies common problems in healthcare, works with front-line staff, and uses mixed-methods approaches with academic rigor to create, educate and implement, evaluate, disseminate, and sustain potential solutions.



**Rita K. Jew, PharmD, MBA, President, Institute for Safe Medication Practices (ISMP)**

Rita K. Jew is President at the Institute for Safe Medication Practices (ISMP) where she provides leadership in advocacy of ISMP's mission and vision to stakeholders and develops and implements strategic goals. She also provides oversight and actively participates in consultation, education, publications, alerts and error reporting programs and oversees the development of new guidelines, programs, products and services. Prior to joining ISMP, Dr. Jew held various leadership positions including Director of Pharmacy at UCSF Health, Executive Director of Pharmacy & Clinical Nutrition Services at CHOC Children's and Clinical Manager at Children's Hospital of Philadelphia. Her 25 plus-year tenure in hospital pharmacies encompassed broad experiences in pharmacy leadership, clinical pharmacy services, formulary management, medication safety, pharmacy operations, centralized pharmacy services, pediatric pharmacy services, healthcare technology and automation, sterile & non-sterile compounding, finance and revenue-cycle, 340B program, CQI/lean, clean room and pharmacy construction, emergency preparedness and establishing pharmacy residency programs.

Dr. Jew presented and published extensively on clinical topics in pediatrics, extemporaneous compounding, vaccines, healthcare technology and automation as well as various topics on pharmacy operations and medication safety. She held adjunct faculty appointments at various Schools of Pharmacy and School of Nursing. She has received numerous awards and accolades from professional organizations.

Dr. Jew received her Pharm.D. from University of California at San Francisco, completed an ASHP-Accredited Residency in Clinical Pharmacy at Thomas Jefferson University Hospital and received her MBA from the Wharton School, University of Pennsylvania. She is a Board-Certified Pediatric Pharmacy Specialist (BCPPS).



**Douglas Braun, PharmD, CSP, CPh, Senior Manager of Partner Development & Strategy, NCODA**

Douglas serves as NCODA's Senior Manager of Partner Development and Strategy. Originally from Brooklyn and now based in Naples, Florida, he has built his career on clinical excellence and strategic leadership. With more than 30 years of experience as a pharmacist, Douglas has strengthened operations and compliance across community, long-term care, and specialty pharmacy settings. As a Consultant Pharmacist, he also supports regulatory compliance at local hospice and crisis/detox facilities. Guided by a strong belief that every cancer patient deserves access to the highest quality care, Douglas is committed to advancing oncology practice standards, supporting staff and healthcare provider development, and helping ensure evidence-based care reaches patients wherever they are treated.



**Clarence Lam, MD, MPH, FACPM, American College of Preventive Medicine (ACPM); Program Director, Preventive Medicine Residency Program, BSPH**

Clarence Lam, MD, MPH serves on faculty and as the program director of the preventive medicine residency program at the Johns Hopkins Bloomberg School of Public Health. Lam is a Phi Beta Kappa graduate of Case Western Reserve University where he completed his Bachelor of Arts in political science and biology. He earned his medical degree from the University of Maryland and his Master of Public Health from Johns Hopkins University. He completed his residency training at Johns Hopkins, where he also served as chief resident, and is board-certified in preventive medicine. In November 2014, Clarence Lam was elected to serve as a state delegate representing District 12, which includes both Howard and Baltimore Counties, in the Maryland General Assembly, where he currently serves on the House Environment and Transportation Committee. He is one of only four physician-legislators currently in the Maryland General Assembly. While in medical school, Lam was elected as the student-body president of the University of Maryland, Baltimore, and he interned on the health affairs staff of the Committee on Oversight and Government Reform of the U.S. House of Representatives where he assisted oversight investigations on drug safety policy. He also served as a biodefense analyst at the Center for Biosecurity of the University of Pittsburgh Medical Center and authored several publications on public health preparedness. From 2009-2014, he served on the legislative staff of Delegate Dan Morhaim, MD in the Maryland General Assembly. Clarence Lam is involved in many community organizations and serves on several non-profit boards of directors, including Healthy Howard, Unified Community Connections (formerly the United Cerebral Palsy of Central Maryland), and as board chair of the Community Action Council of Howard County, which manages the county's food bank, Head Start program, and provides for energy and housing assistance to residents in need. He was a past appointee to the Governor's Commission for Asian Pacific American Affairs and to Howard County's Spending Affordability Advisory Committee.



**Richard O. Dolinar, MD, Arizona Endocrinology Center, Americans For Safe and Effective Medicines**

Dr. Dolinar is a clinical endocrinologist with more than 30 years of private practice experience in Phoenix, Arizona, specializing in diabetes, and serves on the Alliance for Safe Biologic Medicines board. A published author and nationally and internationally recognized healthcare policy expert, he has testified before the U.S. Senate, briefed Congress and presented to the World Health Organization.

Dr. Dolinar is an advisor to the national consumer safety organization, Americans for Safe and Effective Medicines.



**Adam Sulewski, Senior Director, IP Enforcement, U.S. Chamber of Commerce Global Innovation Policy Center (GIPC)**

Adam M. Sulewski serves as the Senior Director for IP Enforcement at the U.S. Chamber of Commerce's Global Innovation Policy Center. At the U.S. Chamber, Adam works to advocate for strong and effective protections for the United States' IP brand and trademark holders. Prior to joining the U.S. Chamber, Adam served for sixteen years at U.S. Customs and Border Protection. Notable roles there include:

- Policy analyst at the National Intellectual Property Rights Center;
- Trade Representative for CBP at the U.S. Embassy – Mexico City, serving four years in Mexico.
- Branch chief at CBP's U.S. – Mexico – Canada Agreement Center, managing all aspects of the once-in-a-generation transition from NAFTA to the new trade agreement;
- U.S. delegate to World Customs Organization and Asia Pacific Economic Cooperation

Adam graduated from Suffolk University Law School in 2009, and is a licensed attorney in Massachusetts and New York. He is a Presidential Management Fellows alumnus. Adam is married to Bruce A. Herr, Jr., a certified registered nurse anesthetist. They make their home in Washington, D.C.

**Michael Stepanovic, PharmD, MS, UNC**

Michael Stepanovic is an assistant professor specializing in Health-System Pharmacy Administration & Leadership. His research focuses on medication quality and safety, substandard and falsified medicines, pharmacy leadership, and expanding non-clinical career pathways for pharmacy students. His work has a particular emphasis on protecting the integrity of the medication supply chain and identifying approaches to reduce the risks posed by poor-quality and falsified medications.

Stepanovic earned his PharmD from Purdue University and an MS in Health-System Pharmacy Administration from the University of North Carolina at Chapel Hill. He completed a PGY1 Acute Care Pharmacy Residency and PGY2 Health-System Pharmacy Administration Residency at the Hospital of the University of Pennsylvania. His professional experience has included roles at AstraZeneca, The Johns Hopkins Hospital, Rush University Medical Center, and the University of Chicago Medical Center.

Stepanovic founded MedTrak, LLC to improve medication tracking and patient safety and IdentifyRx to support the identification of substandard and falsified medicines. He has completed several technology commercialization programs, including NSF and NIH I-Corps fellowships. He is also actively involved in professional organizations including ASHP and the International Pharmaceutical Federation (FIP), where he contributes to global pharmacy standards and leadership initiatives. He also serves as Vice Chair of the Collaborative for Evidence-Based Medicine (CEBM), an organization focused on advancing evidence-based health policy, medication safety, and public understanding of medicines.

**Saleem Alhabash, PhD, Head of Consumer and Scientific Research, A-CAPP Center, MSU**

Saleem Alhabash is a Professor of Public Relations and Social Media at Michigan State University's Department of Advertising + Public Relations and the Associate Director of Research for the Center for Anti-Counterfeiting and Product Protection. He also co-directs the Media and Advertising Psychology (MAP) Lab. His research focuses on the processes and effects of new and social media within the context of persuasion. More specifically, his research investigates the cognitive and emotional responses, and psychological effects associated with using new and social media. His research is geared toward understanding how new communication technologies can be used as persuasive tools, most recently in relation to marketing of alcohol as well as digital aggression across the lifespan. He also studies how new and social media can facilitate cross-cultural and international communication, with emphasis on changing attitudes and stereotypes of foreign nations. In 2014, he was named the inaugural recipient of the American Academy of Advertising's Mary Alice Shaver Promising Professor Award. His research won best article, top paper, and top poster awards at national and international conferences. Saleem received his Ph.D. from the University of Missouri School of Journalism. Pre-academia, he worked in a youth nonprofit organization focusing on media and well-being.



**Albert Wu, MD, MPH, Director of Strategic Collaborations at Johns Hopkins Armstrong Institute for Patient Safety and Quality.**

Albert W. Wu is a practicing general internist and Fred and Juliet Soper Professor of Health Policy & Management in the Johns Hopkins Bloomberg School of Public Health, with Joint Appointments in Epidemiology, International Health, Medicine, Surgery, and Business at Johns Hopkins University. He is director of the Center for Health Services and Outcomes Research and director of Strategic Collaborations for the Armstrong Institute for Patient Safety and Quality. His research and teaching focus on patient outcomes and quality of care. He was co-founder and director of the outcomes research committee of the NIH AIDS Clinical Trials Group and has worked in patient safety since 1988. He was a member of the IOM Committee on Preventing Medical Errors and was Senior Adviser for Patient Safety at WHO from 2007-2009. He leads the online Master of Applied Science in Patient Safety & Healthcare Quality, has authored over 500 peer-reviewed publications and is Editor-in-Chief of Journal of Patient Safety and Risk Management. He coined the term "second victim," and is co-founder and co-director of the RISE (Resilience in Stressful Events) peer support program. He received BA and MD degrees from Cornell University and completed an Internal Medicine residency at the Mount Sinai Hospital and UC San Diego. He was a Robert Wood Johnson Clinical Scholar at UCSF and received an MPH from UC Berkeley.



**Frank A. Tarentino III, Associate Chief of Operations, DEA Northeast Region**

Mr. Frank A. Tarentino III serves as the Associate Chief of Operations for the Drug Enforcement Administration's Northeast Region, which encompasses the States of Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, Pennsylvania, Delaware, Maryland, the District of Columbia, and Virginia.

Mr. Tarentino is a twenty-eight-year veteran of the Drug Enforcement Administration and has served in a wide range of assignments including foreign operations, multi-agency international investigations, and local impact initiatives in domestic offices. His experience has led to a leadership philosophy centered on dismantling drug trafficking organizations at every level through trust, transparency, and strong partnerships with law enforcement agencies at the local, state, federal, and international levels.

Mr. Tarentino joined the Drug Enforcement Administration in 1998 after serving as an officer in the United States Army. As an Airborne Ranger Infantry Officer, he achieved the rank of Captain and was assigned to the 1st Ranger Battalion, 75th Ranger Regiment, United States Army Special Operations Command. Following his military service, he spent seven years as a Special Agent assigned to the DEA New York Division Drug Enforcement Task Force, which is the oldest and largest drug task force in the nation.

**Jillian K. Brady, MS, Advisor, Alliance for Safe Online Pharmacies (ASOP)**

Jillian Brady is an ASOP Global Foundation advisor and a Manager at Faegre Drinker Consulting. She provides strategic and project management support to consortia clients, comprised of representatives from the pharmaceutical industry, United States regulatory agencies and academia. A number of these consortia focus on joint technology development and data-sharing initiatives, where Jillian utilizes her experience in scientific research to help clients overcome a wide range of technical and regulatory challenges. Jillian is an experienced research scientist with insight and interest in biochemistry, genetics and molecular and cell biology. She spent several years working as a research specialist at Johns Hopkins University School of Medicine in the Viral Hepatitis Center and as a research fellow in the National Human Genome Research Institute, where she helped to diagnose and study the pathophysiology of inherited disorders of inflammation. Prior to joining the firm, Jillian completed a policy fellowship in the U.S. House of Representatives, focusing on issues surrounding Food and Drug Administration (FDA) regulations, Medicare and Medicaid.

**Timothy Mackey, PhD, Professor, UC San Diego; & Director, Global Health Policy Institute UC San Diego**

Tim Ken Mackey is a Professor in the Global Health Program at UC San Diego and is also the CEO and co-founder of S-3 Research, a public health data science company that conducts online monitoring and investigation work to address illicit online markets. He is also the Director of the Global Health Policy and Data Institute and the Editor-in-Chief of JMIR Infodemiology. He holds a BA in Political Science-International Relations, a Master's Degree in Health Policy & Law, and also earned his PhD in Global Public Health from the joint doctoral program at UC San Diego - San Diego State University. He has co-authored over 270 manuscripts on topics including global health, technology, data science, substance use disorder, and health policy. Dr. Mackey is a successful entrepreneur and scientist and has been featured in numerous media outlets (NY Times, The Today Show, NBC News, etc.), and has acted as a consultant for several domestic and international organizations including the Department of Justice, World Health Organization, and others.

**Marya Lieberman, PhD, Nancy Dee Professor of Cancer Research, University of Notre Dame**

Marya Lieberman is the Nancy Dee Professor of Cancer Research at the University of Notre Dame. She was the 2025 recipient of the ACS Gustavus John Esselen Award for Chemistry in the Public Interest. Her lab develops paper microfluidic devices and kits for use in field settings, including paper analytical devices used to screen pharmaceutical quality in Africa, carbon fiber filters that can identify lead and copper contamination in tap water, and sample collection kits that help parents locate leaded paint, soil, or dust in their homes. She is currently on the hunt for substandard and fake anticancer drugs in sub-Saharan Africa.



**Daniel Estrada, CEO, SIGNA**

Daniel Estrada Duque is a lawyer, with postgraduate training in copyright, industrial property, and technology and business contracts, plus research methods training. He is a Reserve Lieutenant in the Colombian National Police. With 10+ years in brand protection and product security, he is the CEO of Signa Inc., an AI-driven anti-counterfeiting platform operating across the Americas. He also serves on the board of the Colombian Legaltech Association and speaks on technology-enabled enforcement in regulated consumer goods.



**Manuela Dorado, MPH, BESAFE, JHU**

Manuela Dorado Novoa, MPH, is a public health researcher and data analyst with over seven years of research experience spanning neuroscience, epidemiology, global health, and health systems. She earned her Master of Public Health from the Johns Hopkins Bloomberg School of Public Health and her Bachelor of Science in Neuroscience from the University of Washington.

At Johns Hopkins, Manuela is part of the BESAFE team, where her work focuses on research related to substandard, falsified, and diverted medical products and medical devices, including evidence synthesis, study development, and qualitative research. Her public health experience has also included work with the Institute for Health Metrics and Evaluation at the University of Washington, contributing to global health research and epidemiologic modeling, as well as data analysis and reporting for public programs.

Prior to transitioning into public health, Manuela conducted bench neuroscience research using non-human primate models, with a focus on learning, memory, and Alzheimer's disease. Her broader research experience spans infectious diseases, reproductive and maternal health, neurodegenerative disease, and global disease burden estimation. She has experience conducting systematic reviews and meta-analyses, developing research protocols and data collection tools, and translating complex data into findings that can support public health decision-making.



## **Dinh Lê, Senior Manager, Global Brand Protection - MedTech, Johnson & Johnson**

Dinh Lê has spent the last two decades in the medical device and MedTech industry at Johnson & Johnson (JNJ). He had served as a sales consultant to surgeons and nurses in operating rooms, led multi-specialty sales teams, and launched and supported critical medical devices in the US and globally. Shortly after the pandemic, he brought all his commercial experiences in MedTech to the Global Brand Protection Team at JNJ, where he has been leading the fight against illegal medical devices.

Dinh believes that the most effective way to keep patients safe from illegal medical devices is not only reducing the supply but also reducing user demand. For that reason, he is passionate about educating the healthcare community about the risks of illicit medical devices and makes it his mission to democratize information and empower healthcare workers. Together with the JNJ Global Brand Protection team, they have educated over 2,000 healthcare workers and law enforcement professionals in 2026 about the risks and dangers of illegal medical devices. Through the collaboration with Johns Hopkins' BESAFE initiative, he hopes to activate other key stakeholders in the healthcare industry and protect many more innocent patient lives together.



## **Jorge Humberto Restrepo Zapata, Coordinator of Extension, Faculty of Health, Universidad Santiago de Cali; Director, Pharmaceutical Technology Program**

He is a professional with extensive experience in higher education and a solid background in teaching, academic management, and institutional leadership in the health field. Throughout his career, he has contributed to the development of human talent, participating in academic and pedagogical processes aimed at developing professional skills, educational quality, and comprehensive training. He has held various academic leadership roles, including coordinating the Health Faculty's Extension program and directing the Pharmacy Regency Technology program. In these roles, he has been involved in academic planning, curriculum management, coordinating multidisciplinary teams, and strengthening institutional initiatives that impact the educational community. His experience in both teaching and administrative roles has allowed him to develop a comprehensive perspective on the challenges of higher education especially in training health professionals and in building academic processes that are relevant, innovative, and responsive to the needs of the environment. They stand out for their leadership, management skills, focus on continuous improvement, and commitment to academic excellence. Their track record as a teacher and administrator forms the basis of their work as a speaker, from a perspective that aims to share experiences, knowledge, and reflections that help strengthen education and professional development.



## **Emily Grove, HSI Special Agent, Homeland Security Investigations**

Emily Grove is a Special Agent with the Homeland Security Investigations (HSI) Washington, D.C. Global Trade Fraud Group. In this role, she investigates commercial fraud and intellectual property rights, along with other U.S. Customs violations. So far, she has prosecuted several organized retail crime groups who use fraudulently obtained gift cards to purchase high demand exports at the federal and state level. Emily brings 14 years of law enforcement experience to her group. Prior to her HSI position, she worked as a Police Officer in Henrico County Virginia. She is also a Navy Reserve Senior Chief Petty Officer with 14 years of military service.



## **Jeremy F. Suggs, ScD, Director, Device Safety Group, ECRI**

Dr. Jeremy Suggs is an engineer, healthcare accident investigator, and device safety expert who determines how medical technology fails patients and clinicians, and what health systems and industry leaders can do to prevent recurrence.

Jeremy leads ECRI's device evaluation program and performs independent, third-party investigations of healthcare incidents involving medical devices, pairing hands-on comparative product testing with rigorous accident and hazard investigation.

Jeremy has led comparative assessments and hazard and accident investigations across technologies ranging from surgical tools, anesthesia, and physiologic monitoring to ultraviolet room disinfection, patient lifts, and clinical communication systems.

As a consultant, he provides technical assistance in patent infringement and product liability litigation, reviews complaint databases, and analyzes potential injury mechanisms in personal injury litigation. His product development work has focused primarily on spine implants. He earned his doctorate in Mechanical Engineering at MIT, with a focus in orthopedic biomechanics and reconstruction after total knee replacements.

Jeremy's mix of research, industry, and forensic experience equips him to evaluate and improve medical devices and healthcare technologies from the perspective of designers, regulators, patients, and clinical users.



## **Lev Kubiak, VP, Senior Advisor, Pfizer**

Lev J. Kubiak has been a Federal Law Enforcement Officer for the past 22 years. In his position as the Assistant Director, International Operations, Mr. Kubiak is responsible for the operational oversight of 66 offices and 8 Department of Defense Liaisons in 47 countries with over 400 personnel who conduct investigations against terrorist and other criminal organizations that threaten our national security. Previously, Mr. Kubiak served as the Director for the National Intellectual Property Rights Coordination Center (IPR Center), located in Arlington, VA. The center operates as a task force of 21 partner agencies (17 key U.S. agencies and four international partners) who together stand at the forefront of the U.S. government's response to global intellectual property theft. In addition to leading the IPR Center, Mr. Kubiak was responsible for U.S. Immigration and Customs Enforcement's (ICE) Homeland Security Investigations' (HSI) criminal trade fraud investigations program. Prior to assuming the role of Director in August 2011, Mr. Kubiak served in Buffalo, NY as the HSI special agent in charge. Other key leadership positions have included deputy assistant director for ICE's international policy and programs division and deputy director for the Container Security Initiative, a national security program focused on securing global trade and the international movement of cargo containers. Mr. Kubiak began his career in government service in 1992 when he joined the U.S. Customs Service in Washington, D.C. He began his federal investigative career in 1995 when he became a U.S. Customs special agent assigned to the Detroit, MI field office. Prior to his career in government service, Mr. Kubiak was an adjunct faculty member at George Mason University in Fairfax, VA, where he also received his Masters of Public Administration. He obtained a Bachelor of Arts degree from Mercyhurst University in Erie, PA. In 2013 he was elected to Mercyhurst's board and now serves as a trustee.



## **Jennifer Golbeck, PhD, University of Maryland**

Jen Golbeck is a computer scientist and a Professor at the University of Maryland. She has degrees in economics, computer science, and psychology from the University of Chicago and Harvard, and PhD in computer science from the University of Maryland. Her research focuses on artificial intelligence, social media, and malicious online behavior. She frequently appears on NPR, MSNBC, and is the author of *The Purest Bond: Understanding the Human-Canine Connection*.



## **Katie Paul, Director, Tech Transparency Project**

Katie A. Paul is the director of the Tech Transparency Project (TTP), where she specializes in tracking extremism, disinformation, and criminal activity on online platforms such as Facebook. She also serves as co-director and co-founder of the Antiquities Trafficking and Heritage Anthropology Research (ATHAR) Project and a founding member of the Alliance to Counter Crime Online (ACCO). Previously, Katie served as chief of staff and a research fellow at the Antiquities Coalition, a Washington, DC-based non-profit dedicated to combating cultural racketeering. She holds a bachelor's degree from Miami University (OH) with a double major in Anthropology and Ancient Greek and earned an M.A. in Anthropology at The George Washington University.



## **Bonnie Patten, JD, Truth in Advertising / TINA.org**

Bonnie Patten is Executive Director of Truth in Advertising (TINA.org), a non-profit consumer advocacy organization focused on protecting consumers from false and deceptive marketing. Since its inception, TINA.org has filed more than 300 legal actions, and state and federal agencies have obtained monetary judgments of more than \$1 billion against wrongdoers based on TINA.org's legal work. Ms. Patten has testified before Congress on issues related to consumer protection, deceptive marketing and economic justice, and she is a regular commentator in the media including appearances on NBC, CBS, ABC, and BBC, in publications including The New York Times, The Wall Street Journal, The Washington Post, and The Economist, and on podcasts such as The Dream. She is the 2019 recipient of the Florence Kelley Consumer Leadership Award by the National Consumers League. She earned her J.D. from Boston University and her B.A. from the University of Pennsylvania.



## **Kari Kammel, MA, JD, Director A-CAPP Center**

Kari Kammel is Director of the A-CAPP Center at Michigan State University, where she leads research and education on brand protection and trademark counterfeiting. An attorney licensed in Illinois and Michigan, she has testified before the U.S. Senate and House Judiciary Committees and teaches law at MSU. Her work has been featured in NPR, Reuters, CNN, CNBC, and USA Today. She holds degrees from DePaul University, the American University in Cairo, and the University of Chicago.



## **Humayun Chaudhry, DO, MS, President & CEO, FSMB**

Dr. Humayun "Hank" Chaudhry is President and CEO of the Federation of State Medical Boards. A graduate of NYU, NYIT College of Osteopathic Medicine (NYITCOM) and the Harvard TH Chan School of Public Health, Dr. Chaudhry did his internship at St. Barnabas Hospital, New York, followed by an ACGME-accredited Internal Medicine residency at NYU Langone-Long Island Hospital, where he served as Chief Resident. He is a Past President of the American College of Osteopathic Internists (ACOI).

Dr. Chaudhry served five years as a DIO at Long Beach Medical Center, New York, and six years as Chair of the Department of Medicine and Assistant Dean for Pre-Clinical Education at NYITCOM. He rose to the rank of Major in the U.S. Air Force Reserves, where he was a Flight Surgeon. He served as Health Commissioner for New York's Suffolk County from 2007-2009 and is the author or co-author of over 80 peer-reviewed articles and co-author of two books. From 2016-2018, he was Chair of the International Association of Medical Regulatory Authorities. In 2022, he was listed by Modern Healthcare as one of the 100 Most Influential People in Healthcare.



## **Helen Kinsman Hughes, MD, MPH, Medical Director, Office of Telemedicine at Johns Hopkins Medicine**

Dr. Hughes serves as Medical Director for Johns Hopkins Medicine's Office of Telemedicine and Medical Director of Pediatric Telemedicine for the Johns Hopkins Children's Center. She is a medical informaticist and co-chairs the Johns Hopkins Patient Family Centered Design (MyChart) committee. In addition to these roles, Dr. Hughes is an Associate Professor of Pediatrics at the Johns Hopkins University School of Medicine. After earning an undergraduate degree at Haverford College, Dr. Hughes attended medical school at Johns Hopkins School of Medicine and received a Master of Public Health from the Johns Hopkins Bloomberg School of Public Health. She completed a residency in pediatrics and served as Chief Resident at Johns Hopkins, where she stayed on to complete a research fellowship in General Academic Pediatrics. Dr. Hughes is a national leader in the field of telemedicine and patient-facing digital health technologies. Dr. Hughes and team have won the AAMC's Telehealth Equity Catalyst Award for three consecutive years (2022, 2023, and 2024). In 2023, she was selected to join the American Telemedicine Association's Clinician Council – a group of approximately 35 clinician telehealth leaders who are developing clinical practice guidance for the nation's leading telemedicine professional society.



**Bruce A. Huhmann, PhD, Professor, Department of Marketing, Associate Director, VCU Center for Professional Selling**

Bruce A. Huhmann received his Ph.D. in Marketing from the University of Alabama in 1999. Before joining the faculty of the School of Business at Virginia Commonwealth University as the Department Chair of Marketing from 2017 to 2026, he was Wells Fargo Professor of Marketing and Director of the Daniels Fund Ethics Initiative at New Mexico State University. His research has appeared in the Journal of Consumer Research, Journal of the Academy of Marketing Science, Journal of Advertising, European Journal of Marketing, Journal of Business Research, International Journal of Advertising, Journal of Marketing Communications, Journal of Consumer Affairs, Psychology & Marketing, Journal of Public Policy & Marketing, and several other journals and scholarly books.



**Marc Taraban, PhD, University of Maryland**

Dr. Taraban holds Ph.D. in Chemical Physics/Biophysics. His background is Spin Chemistry involving Chemically Induced Dynamic Nuclear Polarization (CIDNP) in fast chemical reactions carried out inside the NMR probe. His most recent career includes the positions of Visiting Assistant Professor at the Department of Chemistry, University of Utah where he explored protein/enzyme chemistry with Prof. Charles Grissom and structural biology/biophysics applications of SAXS and SANS with Prof. Jill Trehwella. He is currently an Associate Research Professor at the University of Maryland.

Dr. Taraban has more than 40 years of experience in nuclear magnetic resonance and biophysics. His current research focus is on the NMR relaxometry using water as a reporter for analysis of pharmaceuticals including gene and cell therapy products. He has more than 90 peer-reviewed publications and 14 issued and multiple pending patents in the field of water proton NMR applications.



## **Leigh Verbois, PhD, Rx 360**

Dr. Verbois is a recognized leader in global regulatory science, pharmaceutical quality, and supply chain integrity, with a distinguished career spanning executive leadership at the U.S. Food and Drug Administration (FDA), the U.S. Pharmacopeia (USP), and the nonprofit sector.

Currently, Dr. Verbois serves as Chief Executive Officer of Rx-360, an international nonprofit consortium established in 2009 to unite the pharmaceutical and medical device industries in strengthening the security and integrity of the global healthcare supply chain. Under her leadership, Rx-360 brings together industry peers to share information, advance collaborative processes, and facilitate audit collaboration focused on the quality and integrity of materials throughout the pharmaceutical supply chain. The consortium's work is grounded in a shared commitment to protecting patient safety and ensuring the safe and reliable distribution of life-saving medicines.

Prior to joining Rx-360, Dr. Verbois served as Director of the Office of Drug Security, Integrity and Response within the FDA's Center for Drug Evaluation and Research (CDER) Office of Compliance. In this role, she led strategic oversight of pharmaceutical import and export activities, recalls, and critical supply chain compliance and enforcement programs. Throughout her distinguished FDA career, Dr. Verbois held several senior leadership positions with global impact. Most recently, Dr. Verbois served as Senior Director of Global Regulatory and Laboratory Programs at USP, where she advanced international regulatory and quality initiatives supporting the availability of safe, effective, and quality-assured medicines.

Across her career, Dr. Verbois has shaped policies, partnerships, and strategies addressing some of the most complex challenges facing the global pharmaceutical supply chain. Her work reflects a sustained commitment to strengthening transparency, accountability, collaboration, and resilience across the healthcare ecosystem — all with the ultimate goal of protecting patients worldwide.

**Elizabeth Waldorf, Head of Global Traceability and Standards, TraceLink**

Elizabeth Waldorf serves as the Head of Global Traceability and Standards at TraceLink, leveraging over 30 years of leadership experience across the manufacturing and solution-provider sectors. A recognized authority on regulatory transformation and pharmaceutical supply chain security, she specializes in deconstructing complex, fragmented global mandates into scalable, standardized traceability models that drive compliance and operational resilience.

Elizabeth's influence on the architecture of global supply chain standards is foundational. She is an active leader across major industry bodies, serving as a member of the GS1 Architecture Group since 2017, a member of the Healthcare Distribution Alliance (HDA) Network Provider Advisory Board, and tri-chair of the Open Credentialing Initiative (OCI) Policy and Architecture team. She also drives progress within the Partnership for DSCSA Governance (PDG) and the industry NDC Coordination and Implementation Forum. By uniting these multi-disciplinary networks, Elizabeth bridges the gap between technical data exchange and practical business operations to accelerate the adoption of interoperable standards that safeguard public health.

In 2022, Elizabeth was honored with the prestigious GS1 Ken Traub Industry Standards Award for her career-long contributions to global systems integration. As a member of the GS1 Healthcare and GS1 US Executive Leadership teams, she remains a primary advocate for supply chain digitalization. She currently co-chairs critical industry workgroups—including GS1 Visibility, GS1 US RxSecureSupplyChain, and the GS1 US New NDC Format—serving as a standard-bearer for integrating data as the bedrock of the modern digital health ecosystem.

**Traci Green, PhD, MSc, Professor and Director, Opioid Policy Research Collaborative at the Heller School for Social Policy and Management, Brandeis University; Adjunct Professor and Deputy Director, COBRE on Opioids and Overdose at Brown University Health**

Dr. Green is an epidemiologist whose research focuses on drug use, opioid use disorder, and drug-related injury. She earned a Master of Science in Epidemiology and Biostatistics from McGill University and a PhD in Epidemiology from Yale University. She is Professor and Director of the Opioid Policy Research Collaborative at Brandeis University where she oversees research on the drug supply, overdose prevention, and risk mitigation following law enforcement and policy actions. She also co-directs the Center of Biomedical Research Excellence (COBRE) on Opioids and Overdose at Brown University Health's Rhode Island Hospital, and is an Adjunct Professor of Emergency Medicine and Epidemiology at the Warren Alpert School of Medicine at Brown University and the Brown School of Public Health. Dr. Green created the web app platform [www.streetcheck.org](http://www.streetcheck.org) to support the growth and excellence of community drug checking. She helped co-found [www.prescribetoprevent.org](http://www.prescribetoprevent.org) for prescribers and pharmacists and its companion site [www.prevent-protect.org](http://www.prevent-protect.org) for families, patients, and community organizations to improve naloxone access.



**Josh Bolin, Associate Executive Director, Government Affairs and Innovation, National Association of Boards of Pharmacy (NABP)**

Josh Bolin serves as Senior Advisor, NABP and Senior Vice President, Pulse by NABP. In his current capacity, he is the Association's primary liaison with the boards of pharmacy, state government and federal government agencies, and Congress, and he directs strategic initiatives, partnerships, and innovation. Mr. Bolin leads the Association's work on Pulse, NABP's platform for supply chain security and diversion detection, and he works with NABP member boards of pharmacy on uniform processes and tools with respect to DSCSA.

Mr. Bolin has testified before Congress and regularly engages the United Nations and other international organizations on supply chain security and patient safety. He leads NABP's participation in Operation African Star 2 and Operation MedTrace, international efforts to detect substandard and falsified medicines and protect patients across global supply chains.

Since joining NABP in 2005, Mr. Bolin has worked on the development of PMP InterConnect®, multiple pharmacy accreditation and inspection programs, including accreditation programs for durable medical equipment and specialty pharmacy, and inspection programs for the prescription drug supply chain, sterile and nonsterile compounding, and nuclear pharmacy. Mr. Bolin also worked with NABP's member boards of pharmacy to develop standards for exchange and sharing of licensure and disciplinary data, NABP's Universal Inspection Form, and Multistate Inspection Blueprint, which are all tools to assist the boards of pharmacy in sharing data and conducting inspections in a uniform manner.



**Charlie Preston, MD, MPH, DipABPM, DipABLM, Senior Program Officer, Gates Foundation**

Charles Preston is a senior program officer at the Gates Foundation working on the regulatory systems team within the global health division. He has worked on regulatory strengthening in roles at US FDA, WHO/PAHO, and now Gates for the past 15 years. He is a public health physician and did his MPH and public health residency training at Hopkins.



## **Jude Nwokike, PhD, MSc, MPH, EALI Access LLC, Formerly Vice President at USP**

Dr. Jude Nwokike brings over 20 years of leadership in medical products development, quality assurance, regulatory systems strengthening, and pharmaceutical systems. As Vice President at USP, he has led global initiatives to ensure the quality and safety of medicines and promoted the adoption of manufacturing standards and regulatory frameworks across nearly 60 countries, removing barriers to accelerate access to life-saving medicines and vaccines.

Before joining USP, Dr. Nwokike served as the U.S. FDA liaison to the Center for Drug Evaluation and Research, supporting the PEPFAR antiretroviral drugs program. He coordinated with pharmaceutical companies to streamline participation in the FDA's expedited review process for ARVs and collaborated with the World Health Organization (WHO) to enhance reliance and timely access to FDA-approved ARVs for global health programs.

Earlier, he held global technical leadership roles advancing product quality assurance, regulatory harmonization, and pharmaceutical supply systems strengthening. His decade in the pharmaceutical industry refined his expertise in product development, manufacturing standards, and delivering quality pharmaceuticals to global markets.

Dr. Nwokike chairs WHO's Global Steering Group for the Coalition of Interested Parties (CIP) Network and received the 2020 IPS Medal Award from the International Pharmaceutical Federation (FIP). A mentor to thousands of experts, he continues to build high-performing teams that drive excellence in global health.

## **Jean Berchmans Uwimana, MD, MPH, MBA, Senior Program Officer, BESAFE Initiative, Johns Hopkins Bloomberg School of Public Health**



Jean Berchmans Uwimana, MD, MPH, MBA, is a Senior Program Officer at the Johns Hopkins Bloomberg School of Public Health, where he works with the BESAFE Initiative on public health strategies to combat substandard and falsified medical products. He completed a dual MPH/MBA at the Bloomberg School of Public Health and the Carey Business School, holds certificates in pharmacoepidemiology and clinical trials, and is a recipient of the Johns Hopkins Sesquicentennial Award. While practicing as a physician in Rwanda, he co-founded a network of over 200 physicians promoting access to quality care. His research interests are in pharmacovigilance, drug safety, and pharmacoepidemiology, with a focus on strengthening quality medical product manufacturing, supply chain, and distribution systems that bridge high-income and low-resource settings.